Background
Screening mammography utilization in Vermont has declined since 2009 during a time of changing screening guidelines and increased interest in personalized screening regimens. This study evaluates whether the breast cancer risk distribution of the state's screened population changed during the observed decline.
Methods
We examined the breast cancer risk distribution among screened women between 2001 and 2012 using data from the Vermont Breast Cancer Surveillance System. We estimated each screened woman's 5-year risk of breast cancer using the Breast Cancer Surveillance Consortium risk calculator. Annual screening counts by risk group were normalized and age-adjusted to the Vermont female population by direct standardization.
Results
The normalized rate of low-risk (5-year breast cancer risk of <1%) women screened increased 8.3% per year (95% confidence interval [CI] = 4.8 to 11.9) between 2003 and 2008 and then declined by −5.4% per year (95% CI = −8.1 to −2.6) until 2012. When stratified by age group, the rate of low-risk women screened declined −4.4% per year (95% CI = −8.8 to 0.1; not statistically significant) for ages 40 to 49 years and declined a statistically significant −7.1% per year (95% CI = −12.1 to −2.0) for ages 50 to 74 years during 2008 to 2012. These declines represented the bulk of overall decreases in screening after 2008, with rates for women categorized in higher risk levels generally exhibiting small annual changes.
Conclusions
The observed decline in women screened in Vermont in recent years is largely attributable to reductions in screening visits by women who are at low risk of developing breast cancer. Screening mammography reduces mortality from breast cancer through early detection (1) ; however, there is disagreement about optimal screening regimens (2, 3) . This is in part because of new evidence concerning the harms and benefits of mammography (4), including concerns regarding overdiagnosis (5) . Especially for women aged less than 50 years (6), these concerns have led to an emphasis on individualized decision-making approaches to screening participation and interval (7, 8) .
Risk-based approaches to breast cancer screening have been increasingly emphasized in recent years (7, (9) (10) (11) (12) . This trend has paralleled the 2009 US Preventive Services Task Force (USPSTF) recommendation that the decision to screen before age 50 years should be based on individual factors and patient context (13) , and the American Cancer Society's 2007 recommendation that mammography should be supplemented with magnetic resonance imaging for high-risk women of any age (14) . Health-care providers use a wide variety of risk assessment strategies (15) , with family history used as the predominant clinical discriminant (16) (17) (18) . Additionally, both patients and providers can quantitatively assess the individual risk of developing breast cancer within 5 years using online calculators that implement the Breast Cancer Risk Assessment Tool model and the more recent Breast Cancer Surveillance Consortium (BCSC) model, which also includes mammographic breast density (19) (20) (21) (22) .
Patient utilization of screening mammography is known to vary by personal breast cancer risk (23) (24) (25) , as well as by a number of factors, including educational attainment, health-care access, and community socioeconomic status (26) (27) (28) (29) (30) (31) . However, it is not clear how the risk profile of women using screening mammography has changed during the recent period of changing screening guidelines, scientific debate, and media controversy.
We previously reported a decline in breast cancer screening rates in Vermont after the 2009 USPSTF recommendations using a statewide mammography registry (32) . The purpose of this study was to evaluate whether the breast cancer risk distribution of the screened population in Vermont has changed during the observed decline in utilization. Using a cross-sectional analysis of statewide registry data, we examined the distribution of breast cancer risk among the screened population in Vermont between 2001 and 2012.
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Methods

Data
The Vermont Breast Cancer Surveillance System has collected longitudinal patient data regarding mammography screening and breast cancer outcomes in Vermont since 1994. It is part of both the National Cancer Institute's BCSC (33) and the recently formed Population-based Research Optimizing Screening through Personalized Regimens program. At each screening mammography visit to any breast imaging facility in Vermont, the patient completes a standardized questionnaire that includes health history and demographic information. Radiologists and mammography technologists provide information on the clinical mammography findings and the reason for the visit. This study was Health Insurance Portability and Accountability Act compliant and was approved by the University of Vermont Institutional Review Board with a waiver of informed consent. Approximately 5% of the women in the Vermont Breast Cancer Surveillance System indicated that they did not wish their data to be used in research through an opt-out mechanism and were thus excluded from the study.
Study Population
Our sample consists of women aged 40 to 74 years who had screening mammography examinations in Vermont between 2001 and 2012. Data from one imaging facility (representing approximately 11% of the mammograms performed in Vermont) was excluded because of incomplete data during the study period. Mammography examinations of women reporting a personal history of breast cancer (n = 28 610), breast augmentation (n = 4954), or race/ethnicity of Native American (n = 1295) were excluded from the study because the BCSC risk model is not validated for those groups (34) . In instances of women who received multiple screening examinations within a calendar year, the first mammogram was retained and subsequent examinations excluded (n = 2234) so that the sample is restricted to one screening mammography visit per woman per year. The total sample for all years included 588 429 screening mammography examinations among 121 473 individual women.
Measuring Individual Breast Cancer Risk
We used the BCSC risk model in SAS software version 9.3 (SAS Institute, Cary, NC) to assess a woman's 5-year risk for breast cancer at the time of each recorded mammogram (21, 34) . The model calculates an individual's risk of developing breast cancer based on the following variables: age, breast density as defined by the American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) (35), first-degree family history of breast cancer, history of biopsy, and race/ethnicity. The resultant risk scores were grouped according to the following risk categories: low (<1%), average (1%-1.66%), intermediate (1.67%-2.49%), high (2.5%-3.99%), and very high (≥4%) (36) .
Statistical Analyses
Our analyses were based on cross-sectional comparisons of screened women across calendar years. A number of our variables of interest had missing data (Table 1) . We created 10 imputed datasets using multivariable imputation by chained equations in Stata software version 13 (StataCorp, College Station, TX). This method generates imputed values based on a set of individual imputation models respective to each variable with missing observations (37) .
The imputation model included all variables in Table 1 , in addition to height, weight, age at menarche, age at first birth, and year of screening (37) . Missing data was similarly distributed across risk categories within each of the BCSC risk model input variables, with the exception of a modestly elevated percentage of missing density data for women categorized as high risk (25% missing vs 13%-18% missing for other risk groups). The model used augmented regression to manage cases of perfect prediction for the density variable, a common occurrence with categorical variables (38) . The screening frequencies and standard errors of imputed variables, as well as the average annual BCSC risk scores, were combined across imputed datasets obtained using Rubin's rules (39, 40) .
Annual population denominators of Vermont women by age were obtained from the US Census intercensal estimates for 2001 to 2009 and the postcensal estimates for 2010 to 2012 (41). The health service area (42) for the excluded imaging facility consists of a single county; thus we excluded that county from the statewide population counts. We used the Census data to normalize and age-adjust the count of annual mammography screenings in each risk group by direct standardization to account for the state's growing representation of older ages over time. The annual age-specific counts of screened women in each risk group were divided by the age-specific Vermont female population in that year, and the resultant rates were combined within risk groups by age-adjustment to the 2001 to 2012 Vermont female population.
Joinpoint regression analyses were performed using software available from the National Cancer Institute (43). The models used weighted least squares regression, with calendar year as the independent variable and the natural logarithm of the age-adjusted normalized utilization rate as the dependent variable. The analyses identified the lines of best fit using a sequence of permutation tests, and we used a maximum of two joinpoints, which identified statistically significant changes in trend at the P less than .05 level. The model also estimated annual percentage change (APC) between points. The directional sign (+/−) and 95% confidence interval of each APC is reported and, using a two-sided test, the APC is considered statistically significant if the confidence interval does not include zero (44) .
results
As presented in Table 2 , there were similar trends in the average risk for women in each age group. , small yet steady and statistically significant declines in rates were observed throughout the study period, with the former exhibiting an APC of −1.5 (95% CI = −2.0 to −0.9) and the latter exhibiting an APC of −2.1 (95% CI = −3.0 to −1.2). There were no statistically significant APCs among normalized rates for very high-risk women (≥4% 5-year risk).
The results of analyses stratified by age group (40-49 and 50-74 years) are shown in Figure 1 , B and C. Throughout the study period, the majority of women screened in the group aged 40 to 49 years were categorized as low risk ( Figure 1B 95% CI = −1.9 to −0.5) and intermediate risk (APC = −2.3; 95% CI = −3.5 to −1.1) occurred over the course of the full study period. Women categorized as high or very high risk in the group aged 40−49 years represent a very small proportion (<1%) of each annual sample, and they exhibited no statistically significant changes in utilization trends throughout the study period.
Most women screened in the group aged 50 to 74 years were identified each year as average or intermediate risk ( Figure 1C 
Discussion
The decline in screening utilization in Vermont is largely attributable to decreases in screening examinations for low-risk women. Since 2008, the normalized utilization rate declined annually by −5.4% (95% CI = −8.1 to −2.6) among low-risk women, whereas average-and higher-risk groups experienced relatively little change.
Although age is a strong determinant of breast cancer risk (15, 45) , our results indicate that the decline in utilization among low-risk women after 2008 is not solely explained by decreases in screening participation by younger women or the underlying population changes in Vermont's age structure. In analyses stratified by age group, we observed that a decline in the normalized rate of screened, low-risk women occurred in both the group aged 40 to 49 years and the group aged 50 to 74 years, accounting for a majority of the overall reduction in screening utilization in each. Notably, this decline in screening for women at low risk was greater in magnitude in the group aged 50 to 74 years. For the group aged 40 to 49 years, women categorized as average or intermediate risk exhibited steady declines in normalized screening levels over the course of the study period, whereas women at low risk exhibited a statistically significant change in trend in 2008.
There are a number of recent studies that characterize breast cancer risk among screened women (6, 21, (45) (46) (47) (48) (49) ; however there has been little examination of trends in risk over time. Strengths of our study include both the availability of long-term data and a reliance on medical record dates, which provide a more accurate representation of screening attendance than self-reported behavior (50) . Additionally, the incorporation of multiple breast cancer risk factors into one index allows for a more comprehensive quantification of risk than relying on any single factor (21) and represents a readily available measurement of risk as opposed to a patient's genetic predisposition.
Nevertheless, certain limitations to this study should be considered. Although we have observed a decline in the normalized levels of low-risk women receiving mammography screening, we cannot assess the decision-making processes that have influenced this trend. To find the normalized rate, the annual age-specific counts of screened women in each risk group were divided by the age-specific Vermont female population in that year, and the resultant rates were combined within risk groups by age-adjustment to the 2001 to 2012 Vermont female population. Five-year BCSC risk score categories: low (<1%), average (1%-1.66%), intermediate (1.67%-2.49%), high (2.5%-3.99%), and very high (≥4%).
trend of women with almost entirely fatty breasts screened in the state, reflecting changes in reporting that were responsive to the American College of Radiology's fourth edition BI-RADS Breast Imaging Atlas (35) . Across the wider BCSC, density reporting has remained generally unchanged since 2003 (54) . Because most of the associated variation in breast density reporting in Vermont occurred before 2008, outside influences on density reporting do not appear to explain the declining mammography utilization rates for women categorized as low risk between 2008 and 2012. Furthermore, although there may be temporal variation in breast density measurement trends, its use as a clinical factor in assessing risk has gained traction in recent years (55) , as evidenced by the national advocacy movement for legally requiring providers to report density findings (56) . Given the dependence of risk assessment on a factor that can be subject to changes in reporting, some caution is needed when analyzing changes in the distribution of risk over time, especially at subnational scales. This will remain important in the coming years as the density distribution may adjust to the parameters of the newly released fifth edition of the BI-RADS Atlas (54) . Finally, the use of the BCSC risk model does not account for all contributors to breast cancer risk, such as paternal inheritance or other genetic factors.
Our findings raise a number of questions and considerations regarding a patient's decision to screen. Although any individual's motivation for seeking screening is complex and not addressed directly here, the wide variation in screening exams for women at low risk between 2003 and 2012 may be an indicator that low-risk patients of any age are more responsive to the public discourse and guidance for breast cancer screening. The climb in utilization observed before the new USPSTF guidelines may in part reflect their 2002 guidelines that were inclusive of a large age range, as well as earlier public health efforts to maximize screening. Utilization rates among low-risk women showed the greatest magnitude increases during that time. Meanwhile, demand for mammography screening may be less variable among women who perceive themselves at higher risk. There is some evidence that self-perceived risk is associated with guideline adherence and more frequent mammography screening (47, 57, 58) , and yet women may tend to not have accurate perceptions about their personal risk (57) . To complicate matters, confusion among the public about the newest screening recommendations is widespread (59) . Finally, the views of primary care providers about mammography screening vary widely (60) (61) (62) , and recommendation by a provider for screening is one of the strongest predictors of women undergoing screening mammography (31) . These considerations highlight the need for further study of patientand provider-level considerations of risk in the decision to screen.
In conclusion, we find that declines in screening examinations for women at low risk of breast cancer account for a majority of the recent declines in mammography screening utilization in Vermont. The potential health implications of these changing patterns in screening utilization are unclear. In a period of overall declines in screening utilization, it is reassuring that utilization has declined most in low-risk women rather than among higherrisk women. Nevertheless, optimal screening strategies based on risk require further evidence to guide clinical practice. The longterm outcomes for breast cancer incidence and mortality associated with these observed changes are unknown, providing an important area of future research and breast cancer monitoring. 
